UBS has maintained a 'Buy' rating for Welltower (WELL) and increased its price target to $232, up from $203, marking a 14.29% hike. This decision follows similar positive adjustments from other major analysts including Wells Fargo, Morgan Stanley, Scotiabank, Evercore ISI Group, and Cantor Fitzgerald. Welltower, a diversified healthcare REIT, owns a portfolio of 2,447 properties across senior housing, medical office, and skilled nursing sectors in multiple countries.

WELL

<p>瑞士銀行（UBS）維持了對 Welltower（WELL）的 “買入” 評級，並將其目標價從 203 美元上調至 232 美元，漲幅為 14.29%。這一決定是繼其他主要分析師如富國銀行、摩根士丹利、斯科舍銀行、Evercore ISI 集團和 Cantor Fitzgerald 的類似積極調整之後做出的。Welltower 是一家多元化的醫療保健房地產投資信託（REIT），在多個國家擁有 2,447 處物業，涵蓋老年住房、醫療辦公室和專業護理等領域</p>

瑞銀將 Welltower Op 的目標價格上調至 232 美元，維持買入評級 | WE